Milla Pharmaceuticals Inc. and the Alter Pharma Group
Announce First Paragraph IV Filing
and Acceptance by FDA
Milla Pharmaceuticals Announces Approval
and Launch of a Generic Version of Sodium
Acetate Injection 2MEQ/mL by Pfizer Inc.
About Milla
Milla Pharmaceuticals is engaged in the development, licensing / acquisition and
commercialization of generic prescription drugs for the U.S. market focused
on niche injectable and solution products for hospitals and clinics.
Our goal is to deliver high quality medicines; via a world-class supply chain,
at affordable prices by leveraging global partnerships with FDA-approved manufacturing facilities from
around the world.
We are excited to partner with high-quality pharmaceutical developers and manufacturers that enjoy a collaborative relationship and value our expertise in product selection, market analysis, R&D, regulatory, quality and operations.
A.forall is a Belgian group of pharmaceutical companies with headquarters in Anderlecht (Belgium) and offices in Ireland and the United States. Employing in total 144 employees, the group distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals and retirement homes.
At the same time, A.forall is a global player on the generics market, with around 30 molecules on the European and US market and a fully stocked pipeline of niche, complex and added value products.
For more information visit A.forall
